NCT03891173View on ClinicalTrials.gov

A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 19, 2019

Primary Completion Date

May 22, 2020

Study Completion Date

May 22, 2020

Conditions
Lung Adenocarcinoma
Interventions
DRUG

L-DOS47

L-DOS47 lyophilized powder reconstituted and diluted for iv injection

DRUG

Cisplatin

Cisplatin concentrate for solution for iv infusion

DRUG

Vinorelbine

Vinorelbine concentrate for solution for iv infusion

Trial Locations (4)

21029

Vinnytsya Regional Clinical Oncological Centre, Vinnytsia

40005

Sumy Regional Clinical Oncological Centre, Sumy

49102

Dnipropetrovsk City Multi-field Clinical Hospital #4, Dnipro

05-400

Europejskie Centrum Zdrowia Otwock, Otwock

Sponsors
All Listed Sponsors
collaborator

KCR S.A.

UNKNOWN

lead

Helix BioPharma Corporation

INDUSTRY

NCT03891173 - A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma | Biotech Hunter | Biotech Hunter